Long-term comparison of everolimus- vs. novolimus-eluting bioresorbable vascular scaffolds

BACKGROUND The vast majority of clinical trials regarding bioresorbable vascular scaffold (BVS) use came from comparison of everolimus-eluting scaffolds with metallic stents, and it remains unclearwhether similar results would be true when a different type of BVS isused. This study sought to evaluate the long-term performance ofnovolimus-eluting bioresorbable vascular scaffolds (nBVSs) comparedwith everolimus-eluting bioresorbable vascular scaffolds (eBVS).METHODS A total of 140 patients with nBVS (n ¼ 202 before exclusion) and 98 patients with eBVS (n ¼ 135 before exclusion) wereincluded in current study. After propensity-score matching, 98 patients treated with 135 eBVSs were compared with 98 patients treatedwith 136 nBVSs. The primary outcome was the 3-year rate of majoradverse cardiovascular events, defined as the composite of cardiacdeath, target vessel myocardial infarction, and target lesionrevascularization.